BioSpectr
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Sahajanand Medical Technologies raises Rs 140 Cr from Anchor Investors

15 October 2026 | News

Ahead of its initial public offering (IPO), which opens for public subscription on Thursday, October 15, 2026

Sahajanand Medical Technologies, which is a Class III and Class C/D medical devices company with a portfolio of technologically advanced medical devices across vascular and structural heart intervention, has garnered Rs 140 crore from

anchor investors ahead of its initial public offering (IPO), which opens for public subscription on Thursday, October 15, 2026.

The company has allocated 4,071, 634 equity shares at Rs 344 per share to anchor investors. Some of the marquee institutions that participated in the anchor include Allianz Global Investors Fund – Allianz India Equity, Natixis International Funds (Lux) I – Loomis Sayles Global Emerging Markets Equity Fund and Tata AIA Life Insurance Company Limited A/C Whole Life Aggressive Growth Fund ULIF.

Amongst equity- oriented schemes, the company has allocated shares to DSP Healthcare Fund, Nippon Life India Trustee Ltd – A/C Nippon India Small Cap Fund and Whiteoak Capital Flexi Cap Fund, amongst others.

Out of the total allocation of 4,071, 634 equity shares to the anchor investors, 3,025,093 were allocated to 5 domestic mutual funds through 7 schemes.

Motilal Oswal Investment Advisors Limited, Avendus Capital Private Limited, HSBC Securities and Capital Markets (India) Private Limited and Nuvama Wealth Management Limited are the book-running lead managers, and MUFG Intime India Private Limited is the registrar of the offer. The equity shares are proposed to be listed on NSE and BSE.

Sahajanand Medical Technologies Limited has fixed the price band of Rs 327 to Rs 344 per Equity Share of face value Rs. 1/- each for its maiden initial public offer.